Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms

Completed 16 enrolled H. Lee Moffitt Cancer Center and Research Institute Innovive Pharmaceuticals · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the WT-1 vaccine causes an immune response and is safe. The WT-1 vaccine is made up of protein pieces that the patient's immune system can recognize as abnormal.

Timeline

Start: 2008-06
Primary completion: 2013-07
Completion: 2015-02

Publications

Shallis RM, Podoltsev NA. Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission. Curr Opin Hematol. 2021 Mar 1;28(2):110-121. doi: 10.1097/MOH.0000000000000637.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	WT1	Vaccine	—	Subcutaneous
Background	Montanide	Other / unclassified	—	—
Background	sargramostim	Protein / enzyme biologic	70 ug	Subcutaneous

Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms

Summary

Timeline

Publications

Drugs

Indications